Patents by Inventor Jurgen Dinges

Jurgen Dinges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
    Publication number: 20090176783
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 9, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven X. Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
  • N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS
    Publication number: 20090137585
    Abstract: N-Benzoyl arylsulfonamides having the formula are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
    Type: Application
    Filed: February 3, 2009
    Publication date: May 28, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: David J. Augeri, Steven A. Baumeister, Milan Bruncko, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik, Philip J. Hajduk, Aaron R. Kunzer, William Mcclellan, David G. Nettesheim, Thorsten Oost, Andrew M. Petros, Saul H. Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Patent number: 7528282
    Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: May 5, 2009
    Assignee: Abbott Laboratories
    Inventors: Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Patent number: 7511175
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: March 31, 2009
    Assignee: Abbott Laboratories
    Inventors: Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Peer B. Jacobson, Michael E. Brune
  • N-acylsulfonamide apoptosis promoters
    Patent number: 7504512
    Abstract: N-Benzoyl arylsulfonamides having the formula are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: March 17, 2009
    Assignee: Abbott Laboratories
    Inventors: David J. Augeri, Steven A. Baumeister, Milan Bruncko, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik, Philip J. Hajduk, Aaron R. Kunzer, William McClellan, David G. Nettesheim, Thorsten Oost, Andrew M. Petros, Saul H. Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt
  • TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
    Publication number: 20090054426
    Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 26, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
  • Tricyclic pyrazole kinase inhibitors
    Patent number: 7468371
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: December 23, 2008
    Assignee: Abbott Laboratories Inc.
    Inventors: Lee D. Arnold, Jürgen Dinges, Richard W. Dixon, Stevan W. Djuric, Anna M. Ericsson, Kimba Fischer, Alan F. Gasiecki, Vijaya J. Gracias, James H. Holms, Makoto Takeshita, Michael R. Michaelides, Melanie A. Muckey, Paul Rafferty, Douglas H. Steinman, Carol K. Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Q. Zhang
  • PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)
    Publication number: 20080119464
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: January 30, 2008
    Publication date: May 22, 2008
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jurgen Dinges, Stevan Djuric, Ethan Hoff, Hana Kopecka, Jyoti Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing Sham, Paul Wiedeman
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Patent number: 7348346
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: March 25, 2008
    Assignee: Abbott Laboratories
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jürgen Dinges, Stevan W. Djuric, Ethan D. Hoff, Hana A. Kopecka, Jyoti R. Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing L. Sham, Paul E. Wiedeman
  • INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
    Publication number: 20070179186
    Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 10, 2007
    Publication date: August 2, 2007
    Inventors: Jeffrey Rohde, Qi Shuai, James Link, Jyoti Patel, Jurgen Dinges, Bryan Sorensen, Hong Yong, Vince Yeh, Ravi Kurukulasuriya
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Patent number: 7217838
    Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: May 15, 2007
    Assignee: Abbott Laboratories
    Inventors: Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
  • METHOD OF INHIBITING ANGIOGENESIS
    Publication number: 20070043089
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 22, 2007
    Inventors: FORTUNA HAVIV, MICHAEL BRADLEY, JURGEN DINGES, DARYL SAUER, JACK HENKIN
  • METHOD OF INHIBITING ANGIOGENESIS
    Publication number: 20070032527
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 8, 2007
    Inventors: Fortuna Haviv, Michael Bradley, Jurgen Dinges, Daryl Sauer, Jack Henkin
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Publication number: 20060281773
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: January 5, 2006
    Publication date: December 14, 2006
    Inventors: Jyoti Patel, Qi Shuai, James Link, Jeffrey Rohde, Jurgen Dinges, Bryan Sorensen, Martin Winn, Hong Yong, Vince Yeh
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Publication number: 20060149070
    Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: January 5, 2006
    Publication date: July 6, 2006
    Inventors: Jeffrey Rohde, Qi Shuai, James Link, Jyoti Patel, Jurgen Dinges, Bryan Sorensen, Hong Yong, Vince Yeh, Ravi Kurukulasuriya
  • Substituted pyridines having antiangiogenic activity
    Publication number: 20060030557
    Abstract: Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: October 6, 2005
    Publication date: February 9, 2006
    Inventors: Fortuna Haviv, Michael Bradley, Jack Henkin, Jurgen Dinges, Daryl Sauer, Lawrence Kolaczkowski, Anil Vasudevan, David Park
  • Tricyclic pyrazole kinase inhibitors
    Publication number: 20060014816
    Abstract: Compounds of the present invention are useful for inhibiting protein tyrosine kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: March 24, 2005
    Publication date: January 19, 2006
    Inventors: Lee Arnold, Jurgen Dinges, Richard Dixon, Stevan Djuric, Anna Ericsson, Kimba Fischer, Alan Gasiecki, Vijaya Gracias, James Holms, Makoto Takeshita, Michael Michaelides, Melanie Muckey, Paul Rafferty, Douglas Steinman, Carol Wada, Zhiren Xia, Irini Akritopoulou-Zanze, Henry Zhang
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Publication number: 20050215603
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 29, 2005
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jurgen Dinges, Stevan Djuric, Ethan Hoff, Hana Kopecka, Jyoti Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing Sham, Paul Wiedeman
  • Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
    Publication number: 20050209249
    Abstract: The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: March 8, 2005
    Publication date: September 22, 2005
    Inventors: Irini Akritopoulou-Zanze, Daria Darczak, Jurgen Dinges, Stevan Djuric, Ethan Hoff, Hana Kopecka, Jyoti Patel, Zhonghua Pei, Qi Shuai, Kathy Sarris, Hing Sham, Paul Wiedeman
  • Kinase inhibitors
    Patent number: 6831175
    Abstract: Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Qun Li, Keith W. Woods, Gui-Dong Zhu, John P. Fischer, Jianchun Gong, Tongmei Li, Virajkumar Gandhi, Sheela A. Thomas, Garrick K. Packard, Xiaohong Song, Jason N. Abrams, Robert B. Diebold, Jürgen Dinges, Charles W. Hutchins, Vincent S. Stoll, Saul H. Rosenberg, Vincent L. Giranda